尼日利亚等国拉沙热疫苗年龄与性别靶向接种的健康经济学建模研究
该建模研究预测2025至2037年尼日利亚、几内亚、利比里亚和塞拉利昂拉沙热流行区按年龄和性别划分的健康经济负担,并评估靶向不同风险人群接种拉沙热疫苗的成本效果。结果显示靶向15-49岁青少年-成人接种每剂疫苗避免的健康损失最多,最具成本效果的策略取决于疫苗价格。
要点
- 靶向15-49岁青少年-成人接种每10万剂避免的住院最多。
- 疫苗单价2国际元时全员接种最具成本效果,5国际元时靶向青少年-成人最具成本效果。
核心结论
- 靶向青少年-成人接种似乎每剂疫苗产生最大的健康经济价值,但最具成本效果的接种策略取决于疫苗价格。
研究设计与样本
- 疫苗影响建模研究,利用人畜共患病风险图和近期及 ongoing 队列研究流行病学数据构建数学模型,模拟不同风险人群接种策略的成本效果。
主要发现
- 靶向15-49岁青少年-成人、50岁及以上老年人、15-49岁育龄妇女接种分别每10万剂避免住院、死亡和DALY最多。
- 基础假设下,疫苗单价2国际元时全员接种净货币效益最大,5国际元时靶向青少年-成人最具成本效果,10国际元及以上无策略具成本效果。
临床怎么用
- 在拉沙热流行区规划疫苗接种时,可优先考虑靶向15-49岁青少年-成人以最大化每剂健康经济价值。
- 接种策略选择需结合疫苗实际采购价格,单价2国际元时可考虑全员接种,5国际元时靶向青少年-成人更具成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lassa fever is an emerging zoonotic disease endemic to west Africa. Several vaccines aimed at preventing Lassa fever are currently under development, creating a need to assess how best to administer them once licensed for human use. We aimed to project the health-economic burden of Lassa fever from 2025 to 2037 across age and sex groups in subnational administrative divisions of west Africa with endemic Lassa mammarenavirus transmission and to estimate the cost-effectiveness of targeting Lassa vaccination to different risk groups. METHODS: In this vaccine-impact modelling study, we developed a mathematical model using a zoonosis risk map and epidemiological data from recent and ongoing cohort studies to predict the health-economic burden of Lassa fever across age and sex groups in endemic regions. We simulated vaccination campaigns targeting different risk groups to estimate the cost-effectiveness of various strategies for Lassa vaccine administration. Threshold vaccine costs (TVCs), which represent the break-even price per dose of vaccine administered, were estimated in international dollars (INT$ 2023), accounting for health-care costs, productivity losses, and monetised disability-adjusted life-years (DALYs) averted by vaccination. FINDINGS: Lassa fever was estimated to cause 6·23 (95% uncertainty interval (UI) 4·21-8·42) hospitalisations, 0·75 (0·48-1·10) deaths and 31·1 (17·7-52·2) DALYs per 100 000 person-years. Vaccine strategies targeting adolescents-adults aged 15-49, older adults aged 50 years and older, and women of childbearing age (WCBA) aged 15-49 years prevented, respectively, the most hospitalisations, deaths, and DALYs per 100 000 vaccine doses. Under base case assumptions, the most cost-effective strategy (greatest net monetary benefit) was untargeted vaccination for a vaccine costing INT$2 per dose, and targeting adolescents-adults at $5 per dose. At $10 per dose or more, none of the considered strategies were cost-effective. The highest TVC for a single-dose vaccine was estimated at $7·39 (95% UI 4·33-11·60) when targeting adolescents-adults, followed by $6·69 (4·17-9·85) when targeting older adults, $6·10 (3·56-9·74) when targeting WCBA, and $1·94 (1·10-3·10) when targeting children. INTERPRETATION: Targeting of adolescents-adults appears to generate the greatest health-economic value per vaccine dose. However, the most cost-effective vaccination strategy will depend on vaccine price. FUNDING: Coalition for Epidemic Preparedness Innovations.
引用
- Smith DRM, Antony Oliver MC, Holohan KM, et al. Health-economic impacts of age-targeted and sex-targeted Lassa fever vaccination in endemic regions of Nigeria, Guinea, Liberia, and Sierra Leone: a modelling study. Lancet Glob Health. 2026. PMID: 41519155. doi:10.1016/S2214-109X(25)00450-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。